Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,678 | 3,758 | 2,850 | 4,294 | 2,241 |
| TOTAL | $4,937 | $4,166 | $3,307 | $4,835 | $2,735 |
| Non-Current Assets | |||||
| PPE Net | 159 | 197 | 241 | 267 | 306 |
| Intangibles | 0 | 0 | 0 | 0 | 42 |
| TOTAL | $159 | $197 | $241 | $267 | $348 |
| Total Assets | $5,096 | $4,362 | $3,549 | $5,102 | $3,083 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 681 | 684 | 1,141 | 771 | 755 |
| TOTAL | $918 | $906 | $1,364 | $1,184 | $1,490 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $918 | $906 | $1,364 | $1,184 | $1,490 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,888 | 597 | 270 | 206 | 206 |
| Common Shares | 11 | 5 | 30 | 25 | 1 |
| Retained earnings | -114,847 | -112,652 | -110,779 | -108,260 | -106,075 |
| Other shareholders' equity | -580 | -581 | -574 | -598 | -595 |
| TOTAL | $4,178 | $3,456 | $2,185 | $3,918 | $1,593 |
| Total Liabilities And Equity | $5,096 | $4,362 | $3,549 | $5,102 | $3,083 |